Armistice Capital LLC Buys 479,732 Shares of Verrica Pharmaceuticals Inc. $VRCA

Armistice Capital LLC grew its stake in Verrica Pharmaceuticals Inc. (NASDAQ:VRCA) by 75.1% during the 4th quarter, Holdings Channel.com reports. The firm owned 1,118,925 shares of the company’s stock after acquiring an additional 479,732 shares during the period. Armistice Capital LLC owned 0.07% of Verrica Pharmaceuticals worth $9,298,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other large investors also recently modified their holdings of the stock. Bridgeway Capital Management LLC bought a new position in Verrica Pharmaceuticals during the third quarter worth about $52,000. Beck Mack & Oliver LLC acquired a new stake in Verrica Pharmaceuticals during the fourth quarter worth about $100,000. Walleye Capital LLC acquired a new stake in Verrica Pharmaceuticals during the fourth quarter worth about $127,000. Legacy Trust acquired a new stake in Verrica Pharmaceuticals during the fourth quarter worth about $143,000. Finally, HRT Financial LP acquired a new stake in shares of Verrica Pharmaceuticals in the 4th quarter valued at approximately $144,000. 42.45% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades

VRCA has been the topic of a number of research analyst reports. Wall Street Zen downgraded shares of Verrica Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Saturday, May 30th. Zacks Research upgraded shares of Verrica Pharmaceuticals from a “strong sell” rating to a “hold” rating in a report on Monday, May 11th. Finally, HC Wainwright assumed coverage on shares of Verrica Pharmaceuticals in a report on Tuesday, May 26th. They set a “buy” rating and a $12.00 price target for the company. Two investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, Verrica Pharmaceuticals has a consensus rating of “Hold” and an average price target of $14.50.

Verrica Pharmaceuticals Price Performance

Shares of NASDAQ:VRCA opened at $5.83 on Thursday. The company’s 50-day moving average is $6.29 and its 200 day moving average is $6.64. The company has a debt-to-equity ratio of 0.03, a quick ratio of 1.98 and a current ratio of 2.10. The company has a market capitalization of $100.16 million, a P/E ratio of -5.66 and a beta of 1.49. Verrica Pharmaceuticals Inc. has a fifty-two week low of $3.28 and a fifty-two week high of $9.82.

Verrica Pharmaceuticals (NASDAQ:VRCA) last issued its quarterly earnings results on Tuesday, May 12th. The company reported ($0.41) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.59) by $0.18. The company had revenue of $5.02 million for the quarter, compared to the consensus estimate of $4.51 million. Verrica Pharmaceuticals had a negative net margin of 47.97% and a negative return on equity of 1,077.78%. On average, equities research analysts forecast that Verrica Pharmaceuticals Inc. will post -1.84 earnings per share for the current year.

Verrica Pharmaceuticals Company Profile

Verrica Pharmaceuticals Inc is a clinical‐stage biopharmaceutical company focused on the development and commercialization of topical therapies for dermatological conditions. Its lead investigational product, VP-102, is a standardized formulation of cantharidin in a pre-measured applicator designed to treat molluscum contagiosum and common warts. Verrica’s approach emphasizes consistency of dosing and patient convenience, aiming to improve upon off‐label use of existing treatments.

Beyond VP-102, Verrica is advancing VP-103, a next‐generation topical candidate intended to optimize tolerability while maintaining efficacy against viral skin lesions.